Recursion

Vision

Decoding Biology to Radically Improve Lives. Unraveling the exceptional complexity of biological systems and delivering the next generation of biotherapeutics at unprecedented speed and scale can only be achieved by bridging life science and technology.

Approach

Recursion is the leader in digital biology, and has built the world’s most advanced ultra-high throughput wet-lab and machine learning platform. Their ability to generate proprietary, high-dimensional, multi-modal and relatable datasets of human cellular biology at massive scale, and apply advanced machine learning approaches to reveal novel biological relationships, has resulted in a proven, target-agnostic drug-discovery engine.

Recursion (RXRX) went public in April 2021.

Recursion is addressing

• Leap 02 / Provide sustainable organ and tissue replacement
• Leap 04 / Prevent and cure cancer
• Leap 05 / Protect brain and mind
• Leap 10 / Transform health with data